Kyverna Therapeutics, Inc. Operating Expenses
Kyverna Therapeutics, Inc. (KYTX) reported Operating Expenses of $39.56 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-11
- Kyverna Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $39.56M, a 10.93% decline year-over-year.
- Kyverna Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $41.37M, a 12.74% decline year-over-year.
- Kyverna Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $39.28M, a 4.29% decline year-over-year.
- Kyverna Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $38.73M, a 0.11% decline year-over-year.
- Kyverna Therapeutics, Inc. operating expenses for fiscal 2025 was $169.83M, a 19.09% increase from fiscal 2024.
- Kyverna Therapeutics, Inc. operating expenses for fiscal 2024 was $142.60M, a 128.51% increase from fiscal 2023.
- Kyverna Therapeutics, Inc. operating expenses for fiscal 2023 was $62.41M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $39.56M 10-Q · filed 2026-08-11 | $80.92M 10-Q · filed 2026-08-11 | $120.20M derived: sum of 3 quarters · filed 2026-08-11 | $158.93M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $41.37M 10-Q · filed 2026-05-12 | $80.65M derived: sum of 2 quarters · filed 2026-05-12 | $119.38M derived: sum of 3 quarters · filed 2026-05-12 | $163.79M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $39.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $78.01M derived: sum of 2 quarters · filed 2026-03-26 | $122.42M derived: sum of 3 quarters · filed 2026-08-11 | $169.83M 10-K · filed 2026-03-26 |
| 2025-09-30 | $38.73M 10-Q · filed 2025-11-12 | $83.14M derived: sum of 2 quarters · filed 2026-08-11 | $130.54M 10-Q · filed 2025-11-12 | $171.59M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $44.41M 10-Q · filed 2026-08-11 | $91.82M 10-Q · filed 2026-08-11 | $132.86M derived: sum of 3 quarters · filed 2026-08-11 | $171.63M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $47.41M 10-Q · filed 2026-05-12 | $88.45M derived: sum of 2 quarters · filed 2026-05-12 | $127.22M derived: sum of 3 quarters · filed 2026-05-12 | $160.65M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $41.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $79.81M derived: sum of 2 quarters · filed 2026-03-26 | $113.25M derived: sum of 3 quarters · filed 2026-03-26 | $142.60M 10-K · filed 2026-03-26 |
| 2024-09-30 | $38.77M 10-Q · filed 2025-11-12 | $72.20M derived: sum of 2 quarters · filed 2025-11-12 | $101.56M 10-Q · filed 2025-11-12 | $122.94M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $33.44M 10-Q · filed 2025-08-12 | $62.79M 10-Q · filed 2025-08-12 | $84.17M derived: sum of 3 quarters · filed 2025-08-12 | $100.45M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $29.36M 10-Q · filed 2025-05-13 | $50.73M derived: sum of 2 quarters · filed 2025-05-13 | $67.02M derived: sum of 3 quarters · filed 2025-05-13 | $80.32M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $21.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $37.66M derived: sum of 2 quarters · filed 2025-03-27 | $50.96M derived: sum of 3 quarters · filed 2025-03-27 | $62.41M 10-K · filed 2025-03-27 |
| 2023-09-30 | $16.28M 10-Q · filed 2024-11-13 | $29.58M derived: sum of 2 quarters · filed 2024-11-13 | $41.03M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $13.30M 10-Q · filed 2024-08-12 | $24.75M 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $11.45M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |